Meeting
2020 Genitourinary Cancers Symposium
Adjuvant therapy in high-risk renal cell cancer: A systematic review and cumulative meta-analysis.
Authors
Rabbia Siddiqi
Dow University of Health Sciences, Karachi, Pakistan
Rabbia Siddiqi , Irbaz Bin Riaz , Mahnoor Islam , Qurat Ul Ain Riaz Sipra , Alexander J. Ryu , Ammad Raina , M. Hassan Murad , Manish Kohli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 708)
Abstract #
708
Poster Bd #
H6
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).
First Author: Daniel Vargas Almeida
Poster
2020 Genitourinary Cancers Symposium
A randomized, double-blinded clinical trial of royal jelly intake for anticancer effects and suppressing adverse events in renal cell carcinoma patients treated with tyrosine kinase inhibitors.
First Author: Yasuyoshi Miyata
Poster
2018 ASCO Annual Meeting
A meta-analysis of randomized controlled trials for efficacy and safety of vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) adjuvant therapy in high-risk renal cell cancer (RCC).
First Author: Irbaz Bin Riaz
Poster
2018 Genitourinary Cancers Symposium
Association of age and sex with mortality following adjuvant therapy for renal cell cancer (RCC): Subgroup analysis of the ASSURE (E2805) trial.
First Author: Ronac Mamtani